Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Dangelo

Vascular Surgery Fort Myers, FL Medical Doctor

NPI 1447243134 CMS profile 20287

6821 Palisades Park Ct, Suite 1, Fort Myers, FL 33912

Open in the dashboard

General payments

$27,126

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Dangelo of Fort Myers, FL is reported in the CMS Open Payments database as having received $27,126 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,790 30
2024 General $1,109 19
2023 General $3,859 47
2022 General $5,201 80
2021 General $5,730 69
2020 General $2,258 38
2019 General $6,181 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Dangelo
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Anthony Dangelo were reported at $2,790. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Anthony Dangelo Vascular Surgery median Middle half National median
2019 $6,181 $796 $226–$2,363 $163
2020 $2,258 $348 $118–$1,110 $114
2021 $5,730 $471 $158–$1,421 $132
2022 $5,201 $725 $222–$2,183 $149
2023 $3,859 $836 $257–$2,440 $160
2024 $1,109 $909 $252–$2,619 $164
2025 $2,790 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $4,455 47 payments
  2. Silk Road Medical, Inc. $3,654 35 payments
  3. W. L. Gore & Associates, Inc. $3,498 35 payments
  4. Boston Scientific Corporation $2,988 33 payments
  5. Cook Medical LLC $2,666 34 payments
  6. Bard Peripheral Vascular, Inc. $1,205 12 payments
  7. Endologix, Inc. $1,101 8 payments
  8. Medtronic, Inc. $929 15 payments
  9. Janssen Pharmaceuticals, Inc $559 35 payments
  10. Medtronic Vascular, Inc. $537 16 payments
  11. Other $5,534 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $27,126 363 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $2,740 26 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,740 26 payments
  3. Indigo System $2,720 29 payments
  4. Zilver PTX $1,471 16 payments
  5. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,001 10 payments
  6. ENROUTE 0.014 Guidewire $914 9 payments
  7. ENROUTE Transcarotid Stent System $914 9 payments
  8. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $914 9 payments
  9. ENHANCE Transcarotid Peripheral Access Kit $914 9 payments
  10. Cook Medical Zilver PTX $830 13 payments
  11. Other $19,815 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

393

Median for Vascular Surgery: 122

Drug cost

$35,599

Median for Vascular Surgery: $14,135

Branded share of claims

91.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 23 $18,272
Eliquis Apixaban Brand 13 $14,224
Clopidogrel Clopidogrel Bisulfate Brand 268 $2,902
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 56 $162
Diazepam Generic 33 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$318,772

Of which drugs: $287

Medicare patients

485

Average age 76

Services billed

3,971

204 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 53%
Chronic kidney disease 50%
Diabetes 48%
COPD 38%
Heart failure 37%
Atrial fibrillation 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 34 2,341 $246

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record